Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of human Type 2 Diabetic Nephropathy
Open Access
- 20 June 2012
- journal article
- Published by Briefland in Nephro-Urology Monthly
- Vol. 4 (3), 524-529
- https://doi.org/10.5812/numonthly.1954
Abstract
Diabetic nephropathy is a major cause of end-stage kidney disease (ESKD) in patients with type 1 and type 2 diabetes throughout the world. In human glomeruli, expansion of diffuse mesangial matrices, exudative lesions and/or segmental nodular sclerosis are pathological features of diabetic nephropathy. There have been many reports on the pathogenesis and treatment of type 2 diabetes using various animal models. It appears that KK-Ay mice, especially in terms of their immunohistological findings, are a suitable animal model for human type 2 diabetic nephropathy. Many compounds have been reported to be advanced glycation end product (AGE) inhibitors such as aminoguanidine, angiotensin II receptor inhibitors and pyridoxamine, and these are useful in therapeutic interventions for reducing AGEs. Pyridoxamine ameliorates lipid peroxidation and insulin resistance in KK-Ay mice. Combination therapy with angiotensin converting inhibitors (ACE-I) and angiotensin II type 1 receptor blockers (ARB), including an ARB and 1,25-dihydroxyvitamin D3, i.e. anti-hypertensive and anti-reactive oxygen species effects, or with eicosapentaenoic acid (EPA), i.e. anti-microinflammation effect, have shown efficacy in the treatment of diabetic nephropathy in KK-Ay mice. It appears that KK-Ay mice are a useful spontaneous animal model for the evaluation of pathogenesis and treatment in patients with type 2 diabetic nephropathy. Keywords: Models, Animal; Therapeutics; Diabetic NephropathiesKeywords
This publication has 33 references indexed in Scilit:
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialThe Lancet, 2010
- Dietary Intake of Eicosapentaenoic and Docosahexaenoic Acid and Diabetic Nephropathy: Cohort Analysis of the Diabetes Control and Complications TrialDiabetes Care, 2010
- Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increaseProceedings of the National Academy of Sciences of the United States of America, 2008
- Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cellsKidney International, 2007
- Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysisDiabetic Medicine, 2007
- Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanismsKidney International, 2006
- Vitamin D: a negative endocrine regulator of the renin–angiotensin system and blood pressureThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation ReactionsBiochemical and Biophysical Research Communications, 1999
- Determination of Overall Insulin Sensitivity in Diabetic Mice, KKHormone and Metabolic Research, 1982
- Induction of diabetic alterations by goldthioglucose-obesity in KK, ICR and C57BL miceDiabetologia, 1972